ArticleInternational journal of nanomedicine2020
Nanosized Cubosomal Thermogelling Dispersion Loaded with Saquinavir Mesylate to Improve Its Bioavailability: Preparation, Optimization, in vitro and in vivo Evaluation.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Neuroprotective role of cyanidin in Alzheimer's and Parkinson's disease: current insights and the road ahead.Inflammopharmacology · 2026Review
- Cilnidipine Cubosomal Nanogel Patch: Polymer-Nanostructure Synergy for Advanced Transdermal Drug Delivery.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ophthalmic-targeted brinzolamide-laden cubosomal solid lipid nano-vesicular system (Cube-SLNV): design, development, and in vitro and ex vivo characterization.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Formulation and Physicochemical Characterization of Capecitabine-Loaded Cubosomes for Enhanced Drug Delivery System.Drug design, development and therapy · 2026Article
- Detailed Comprehensive Review on Advancement of Cubosomes and their Currently Available Applications.Current pharmaceutical biotechnology · 2026Review
- HSPiP and QbD oriented optimized nanocubosomes for ameliorated absorption of tolterodine tartrate:International journal of pharmaceutics: X · 2025Article
- Poloxamer-Based Biomaterial as a Pharmaceutical Strategy to Improve the Ivermectin Performance.Pharmaceutics · 2025Article
- An Insight into Cubosomal Drug Delivery Approaches: An Explicative Review.Pharmaceutical nanotechnology · 2025Review
- Cubosomes as versatile lipid nanocarriers for neurological disorder therapeutics: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Navigating the Nose-to-Brain Route: A Systematic Review on Lipid-Based Nanocarriers for Central Nervous System Disorders.Pharmaceutics · 2024Review
- Optimization of hyaluronan-enriched cubosomes for bromfenac delivery enhancing corneal permeation: characterization, ex vivo, and in vivo evaluation.Drug delivery · 2023Article
- Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment.Biochemistry and biophysics reports · 2023Article
- Review
- Development and Optimization of Hyaluronic Acid-Poloxamer In-Situ Gel Loaded with Voriconazole Cubosomes for Enhancement of Activity against Ocular Fungal Infection.Gels (Basel, Switzerland) · 2022Article
- Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders.Neurochemical research · 2022Review
- Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation.International journal of nanomedicine · 2022Article
- Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances.Pharmaceutics · 2021Review
- Self-Nanoemulsion Loaded with a Combination of Isotretinoin, an Anti-Acne Drug, and Quercetin: Preparation, Optimization, and In Vivo Assessment.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow bioavailability and poor permeability of the blood-brain barrier are problematic when delivering therapeutic agents and particularly anti-human immunodeficiency virus therapy to the central nervous system. The intranasal route offers an alternative for central nervous system delivery. Cubosomes have been reported as helpful vehicles for intranasal delivery of therapeutics to enable brain targeting.
objectiveIn this study, we aimed to develop the intranasal cubosomal thermogelling dispersion of saquinavir mesylate for central nervous system delivery.
methodsThe Box-Behnken design was applied to study the effect of monoolein, Poloxamer 407, and polyvinyl alcohol as independent factors and the particle size, entrapment efficiency, gelation temperature, and stability index as responses. The optimized cubosomes were evaluated using transmission electron microscopy, ex vivo permeation, and in vivo pharmacokinetics.
resultsThe optimized formula consisting of monoolein (8.96%), Poloxamer 407 (17.45%), and polyvinyl alcohol (7.5%) was prepared and evaluated. Higher values for the steady-state flux, permeability coefficient, and enhancement factor were observed for the cubosomal thermogelling dispersion of saquinavir during ex vivo permeation in comparison with an aqueous suspension of saquinavir. From the pharmacokinetic profile, the relative bioavailability for the intranasal optimized formula was approximately 12-fold higher when compared with oral aqueous suspension and 2.5-fold greater when compared to the intranasal aqueous suspension of saquinavir.
conclusionOverall, the saquinavir-loaded cubosomal thermogelling formulation is promising for central nervous system delivery by intranasal administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.